Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Esslingen Am Neckar – page 3

89 clinical trials in Esslingen Am Neckar, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Esslingen Am Neckar at a glance
89
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

89 trials in Esslingen Am Neckar

Open in trial search

Non-small cell lung cancer stage IV

Recruiting

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AGO Research GmbH

Ovarian epithelial cancer

Recruiting

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Non-small cell lung cancer

Recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Hormone receptor positive breast cancer+2

Recruiting

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut fuer Frauengesundheit GmbH

Double hit lymphoma+7

Recruiting

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Universitaet Des Saarlandes

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia

Recruiting

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Medical Center - University Of Freiburg

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Esslingen Am Neckar

What the registry says about research in the country

01 Lung Cancer Research

Extensive studies focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel treatment combinations and targeted therapies for various disease stages.

  • Advanced and metastatic disease management
  • Post-surgical treatment optimization
  • Combination therapy approaches

Multiple trials investigating immunotherapy combinations and targeted treatments for improved patient outcomes.

02 Breast Cancer Studies

Innovative research targeting hormone receptor-positive and triple-negative breast cancer, exploring new therapeutic strategies and treatment combinations.

  • Early-stage disease management
  • HER2-negative breast cancer
  • Perioperative treatment approaches

Focus on developing personalized treatment strategies and improving survival outcomes.

03 Hematologic Malignancies

Groundbreaking studies in chronic lymphocytic leukemia (CLL) and related blood cancers, evaluating novel drug combinations and treatment duration strategies.

  • Treatment optimization
  • Disease monitoring approaches
  • Targeted therapy combinations

Research aimed at improving treatment responses and patient quality of life.

04 Gastrointestinal Cancers

Research focusing on hepatocellular carcinoma and gastric cancer, investigating innovative combination therapies and surgical approaches.

  • Advanced disease treatment
  • Perioperative therapy
  • Immunotherapy applications

Studies evaluating novel treatment strategies for improved patient outcomes.

05 Gynecologic Oncology

Clinical trials in ovarian cancer and related conditions, studying maintenance therapies and combination treatments for advanced disease.

  • First-line treatment strategies
  • Maintenance therapy optimization
  • Targeted treatment approaches

Focus on improving survival rates and treatment effectiveness.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.